Leading pharmaceutical intermediates manufacturers meeting at Socma's Informex trade show in New Orleans last week say further consolidation in the sector is imminent. Many senior executives from custom fine chemical firms predict a tough year ahead for 2003, with below 10% annual sales growth.
Dow Chemical's business group presidenr/performance chemicals Andrew Liveris, who gave the show's opening keynote presentation, said that the "traditional small-molecule side" of the custom manufacturing business is maturing, with growth at 6%-8%/year. Supplying the biopharmaceuticals sector offers higher growth, but also requires more financial resources than many smaller …
No comments:
Post a Comment